Your browser doesn't support javascript.
loading
Chronic urticaria patients are interested in apps to monitor their disease activity and control: A UCARE CURICT analysis.
Cherrez-Ojeda, Ivan; Vanegas, Emanuel; Cherrez, Annia; Felix, Miguel; Weller, Karsten; Magerl, Markus; Maurer, Rasmus Robin; Mata, Valeria L; Kasperska-Zajac, Alicja; Sikora, Agnieszka; Fomina, Daria; Kovalkova, Elena; Godse, Kiran; Rao, Nimmagadda Dheeraj; Khoshkhui, Maryam; Rastgoo, Sahar; Criado, Roberta F J; Abuzakouk, Mohamed; Grandon, Deepa; Van Doorn, Martijn B A; Rodrigues Valle, Solange Oliveira; De Souza Lima, Eduardo Magalhães; Thomsen, Simon Francis; Ramón, German D; Matos Benavides, Edgar E; Bauer, Andrea; Giménez-Arnau, Ana M; Kocatürk, Emek; Guillet, Carole; Larco, Jose Ignacio; Zhao, Zuo-Tao; Makris, Michael; Ritchie, Carla; Xepapadaki, Paraskevi; Ensina, Luis Felipe; Cherrez, Sofia; Maurer, Marcus.
Afiliación
  • Cherrez-Ojeda I; Universidad Espíritu Santo, Samborondón, Ecuador.
  • Vanegas E; Respiralab, Respiralab Research Group, Guayaquil, Ecuador.
  • Cherrez A; Universidad Espíritu Santo, Samborondón, Ecuador.
  • Felix M; Respiralab, Respiralab Research Group, Guayaquil, Ecuador.
  • Weller K; Respiralab, Respiralab Research Group, Guayaquil, Ecuador.
  • Magerl M; Clinic and Policlinic for Dermatology and Venereology, University Medical Center Rostock, Rostock, Germany.
  • Maurer RR; Universidad Espíritu Santo, Samborondón, Ecuador.
  • Mata VL; Respiralab, Respiralab Research Group, Guayaquil, Ecuador.
  • Kasperska-Zajac A; Institute for Allergology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Sikora A; Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP), Allergology and Immunology, Berlin, Germany.
  • Fomina D; Institute for Allergology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Kovalkova E; Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP), Allergology and Immunology, Berlin, Germany.
  • Godse K; Institute for Allergology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Rao ND; Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP), Allergology and Immunology, Berlin, Germany.
  • Khoshkhui M; Universidad Espíritu Santo, Samborondón, Ecuador.
  • Rastgoo S; Respiralab, Respiralab Research Group, Guayaquil, Ecuador.
  • Criado RFJ; European Center for Diagnosis and Treatment of Urticaria, Medical University of Silesia, Katowice, Poland.
  • Abuzakouk M; European Center for Diagnosis and Treatment of Urticaria, Medical University of Silesia, Katowice, Poland.
  • Grandon D; City Center of Allergy and Immunology, Clinical City Hospital #52, Moscow, Russia.
  • Van Doorn MBA; Department of Allergology and Clinical Immunology, I.M. Sechenov First Moscow State Medical University, Moscow, Russian Federation.
  • Rodrigues Valle SO; City Center of Allergy and Immunology, Clinical City Hospital #52, Moscow, Russia.
  • De Souza Lima EM; Department of Dermatology, D Y, Patil University School of Medicine and Hospital, Mumbai, India.
  • Thomsen SF; Department of Dermatology, D Y, Patil University School of Medicine and Hospital, Mumbai, India.
  • Ramón GD; Allergy Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Matos Benavides EE; Department of Allergy and Immunology, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Bauer A; Department of Allergy and Immunology, Mashhad University of Medical Sciences, Mashhad, Iran.
  • Giménez-Arnau AM; Department of Dermatology, Faculdade de Medicina do ABC, São Paulo, Brazil.
  • Kocatürk E; Allergy and Immunology Department, Cleveland Clinic Abu Dhabi, Abu Dhabi, UAE.
  • Guillet C; Allergy and Immunology Department, Cleveland Clinic Abu Dhabi, Abu Dhabi, UAE.
  • Larco JI; Department of Dermatology, Erasmus MC, Rotterdam, The Netherlands.
  • Zhao ZT; Department of Internal Medicine, Hospital Universitário Clementino Fraga Filho, Rio de Janeiro, Brazil.
  • Makris M; Faculty of Science and Health of Juiz de Fora - SUPREMA - Minas Gerais, Rio de Janeiro, Brazil.
  • Ritchie C; Department of Dermatology, Bispebjerg Hospital, University of Copenhagen, Biomedical Sciences, Copenhagen, Denmark.
  • Xepapadaki P; Instituto de Alergia e Inmunología del Sur, Bahía Blanca, Buenos Aires, Argentina.
  • Ensina LF; Centro de Referencia de Alergia, Asma e Inmunología - Instituto Nacional del Niño, Lima, Peru.
  • Cherrez S; Department of Dermatology, University Allergy Center, University Hospital Carl Gustav Carus, Technical University, Dresden, Germany.
  • Maurer M; Department of Dermatology, Hospital del Mar, IMIM, Universitat Autònoma, Barcelona, Spain.
Clin Transl Allergy ; 11(10): e12089, 2021 Dec.
Article en En | MEDLINE | ID: mdl-34962721
BACKGROUND: Information/communication technologies such as mobile phone applications (apps) would enable chronic urticaria (CU) patients to self-evaluate their disease activity and control. Yet, recently Antó et al (2021) reported a global paucity of such apps for patients with CU. In this analysis, we assessed patient interest in using apps to monitor CU disease activity and control using questions from the chronic urticaria information and communication technologies (CURICT) study. METHODS: The methodology for CURICT has been reported. Briefly, a 23-item questionnaire was completed by 1841 CU patients from 17 UCAREs across 17 countries. Here, we analyzed patient responses to the CURICT questions on the use of apps for urticaria-related purposes. RESULTS: As previously published, the majority of respondents had chronic spontaneous urticaria (CSU; 63%; 18% chronic inducible urticaria (CIndU) [CIndu]; 19% with both), were female (70%) and in urban areas (75%). Over half of patients were very/extremely interested in an app to monitor disease activity (51%) and control (53%), while only ∼1/10 were not. Patients with both urticaria types versus those with CSU only (odds ratio [OR], 1.36 [1.03-1.79]) and females versus males (OR [95% CI], 1.47 [1.17-1.85]) were more likely to be very to extremely interested in an app to assess disease control. CONCLUSIONS: Overall, half of the patients with CU were very to extremely interested in using an app to assess their disease activity and control. Development of well-designed apps, specific to disease types (CSU, CIndU, CSU + CIndU, etc), validated by experts across platforms would help improve the management and possibly outcomes of CU treatment while providing important patient information to be used in future research.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Clin Transl Allergy Año: 2021 Tipo del documento: Article País de afiliación: Ecuador Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Clin Transl Allergy Año: 2021 Tipo del documento: Article País de afiliación: Ecuador Pais de publicación: Reino Unido